Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Alnylam Pharmaceuticals, Inc.
< Previous
1
2
3
4
Next >
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
August 07, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
August 01, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
July 18, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
June 24, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam Issues 2023 Corporate Responsibility Report
May 07, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
May 02, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
April 18, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
April 07, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
March 20, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
March 13, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
March 05, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
February 27, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
February 15, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
January 29, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association
January 09, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
January 07, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
December 13, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam to Webcast Virtual R&D Day
December 06, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
November 30, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk
November 11, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
November 07, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
November 02, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year
October 26, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
October 25, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
October 25, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results
October 19, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
October 09, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023
October 06, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
September 13, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ALNY
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.